2023
DOI: 10.3389/fmed.2023.1265568
|View full text |Cite
|
Sign up to set email alerts
|

Association of the human platelet antigens polymorphisms with platelet count in patients with COVID-19

Kazem Ghaffari,
Mahsa Ashrafi Rad,
Amin Moradi Hasan-Abad
et al.

Abstract: Polymorphism in human platelet antigen (HPA)-1 and HPA-3 (GPIIb/IIIa), HPA-2 (GPIb/IX), HPA-4 (GPIIIa), HPA-5 (GPIa/IIa), & HPA-15 (CD109) was investigated in 86 COVID-19-infected patients with thrombocytopenia (Group A) and 136 COVID-19-infected patients without thrombocytopenia (Group B). HPA genotyping was done by the sequence-specific primers PCR method. Lower HPA-3a and higher HPA-3b (P = 0.028) allele frequencies were seen in Group A than in Group B, and homozygosity for HPA 3b (P = 0.038) allele… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
2

Relationship

2
0

Authors

Journals

citations
Cited by 2 publications
(2 citation statements)
references
References 40 publications
0
2
0
Order By: Relevance
“…All these factors may affect PLT parameters, including MPV levels (Harrison and Goodall, 2016). Among the differences in the clinical conditions of the patients, we can mention the deficiency or decrease in the level of vitamin D in the patients, gender, and HPA polymorphisms (Gur et al, 2015;Alanli et al, 2020;Ghaffari et al, 2023).…”
Section: Discussionmentioning
confidence: 99%
“…All these factors may affect PLT parameters, including MPV levels (Harrison and Goodall, 2016). Among the differences in the clinical conditions of the patients, we can mention the deficiency or decrease in the level of vitamin D in the patients, gender, and HPA polymorphisms (Gur et al, 2015;Alanli et al, 2020;Ghaffari et al, 2023).…”
Section: Discussionmentioning
confidence: 99%
“…To date, 41 human platelet antigens (HPAs) have been described in the Immuno Polymorphism Database (IPD) 1 ( 3 ). Several types of HPAs are involved in different clinical conditions, including venous thrombosis ( 4 ), myocardial infarction ( 5 ), post-transfusion purpura (PTP), platelet (PLT) transfusion refractoriness, alloimmune thrombocytopenia, idiopathic thrombocytopenic purpura (ITP) ( 6 , 7 ), drug-induced immune thrombocytopenia (DITP), fetal/neonatal alloimmune thrombocytopenia (FNAIT) ( 8 , 9 ), and susceptibility to HCV infection ( 10 ).…”
Section: Introductionmentioning
confidence: 99%